Efalizuman is a recombinant humanized monoclonal antibody that binds to CD11a. Because of its side effect, it is to be withdrawn from market in the USA. 

April 9, 2009 — Efalizumab (Raptiva, Genentech, Inc) is undergoing a voluntary, phased withdrawal in US markets because of a potential risk to patients of developing progressive multifocal leukoencephalopathy (PML). Source